Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
网页1 天前 · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse ...
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
网页1 天前 · Earlier on Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist. After ...
News Details - novonordisk.com
网页1 天前 · Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 . The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome 1 .
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
网页1 天前 · Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link].The trial investigated the efficacy and safety of a once-daily 10 ...
Novo Nordisk’s obesity newcomer monlunabant heads into …
网页1 天前 · Novo Nordisk has now announced headline results from a Phase IIa trial with monlunabant investigating the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome. People were equally randomized among the four treatment arms.
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
网页1 天前 · The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic ...
Novo Nordisk shares drop nearly 5% on disappointing obesity pill …
网页1 天前 · LONDON/COPENHAGEN, Sept 20 (Reuters) - Novo Nordisk's (NOVOb.CO) shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant ...
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
网页1 天前 · Friday, shares of Novo Nordisk A/S are sliding following the announcement of safety results of phase 2a clinical trial of Monlunabant compared to placebo in patients with obesity and metabolic syndrome.Monlunabant, formerly INV-202, is a small molecule oral cannabinoid receptor 1 or CB1 inverse agonist. The trial investigated efficacy and safety, and post 16 weeks, people treated with a once ...
Novo Nordisk Stock Declines After Headline Results From Mid …
网页1 天前 · The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg, and 50 mg of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity and metabolic ...
Novo Shares Fall After Mixed Safety Data on New Weight-Loss Drug
网页1 天前 · September 20, 2024 at 9:59 AM EDT. Save. Shares of Novo Nordisk A/Sfell after the Danish drugmaker reported mixed safety data on a molecule it’s testing as part of a next-generation pipeline of ...
- 某些结果已被删除